First manifestation of these diseases is usually between age 30 and 50. Recurrent episodes of activation lead to progressive loss of function of the hands. This leads to a loss of quality of life up to a total loss of the ability to look after oneself, especially in advanced age. Among this group of more than 400 different diseases, the most common are rheumatoid arthritis (RA), psoriasis arthritis, and activated osteoarthritis.
Direct and indirect costs of inflammatory joint diseases are extremely high due to the chronic disease course with intermittent episodes of activation. Rheumatic diseases in fact constitute the biggest financial disease burden for society. Modern, very potent drugs have been introduced over the recent years, offering new effective possibilities in the treatment for these diseases.
mivenion pioneered the development of Rheumascan / Xiralite, a CE approved dedicated solution for early diagnosis of joint diseases in the hands. The medical device Xiralite is a fluorescence optical system optimally adjusted to the microcirculation marker indocyanine green (ICG). The product system aims at rheumatologists, dermatologists, primary care physicians, orthopedic surgeons, and radiologists. nanoICG, a formulation variation of ICG, has been developed to further improve diagnostic efficacy of Rheumascan and to approach ophthalmological applications based on ICG imaging.